STING activation catalyzes type I IFN production, stimulating the release of CXCL9 and CXCL10, which, as previously mentioned, draft the prerequisite tumor-infiltrating lymphocytes and precondition the immunological landscape for a robust checkpoint inhibitor-led anticancer response. This evidence concerns the gene STING1 and neoplasm.